Cargando…
Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods:...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578711/ https://www.ncbi.nlm.nih.gov/pubmed/34778369 http://dx.doi.org/10.3389/fmolb.2021.686313 |
_version_ | 1784596291132588032 |
---|---|
author | Jiao, Zonglin Cao, Shoubo Li, Jianhua Hu, Nan Gong, Yinghui Wang, Linduo Jin, Shi |
author_facet | Jiao, Zonglin Cao, Shoubo Li, Jianhua Hu, Nan Gong, Yinghui Wang, Linduo Jin, Shi |
author_sort | Jiao, Zonglin |
collection | PubMed |
description | Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods: This retrospective cohort analysis included consecutive patients with stage I-III lung cancer who underwent curative resection between December 2010 and December 2014. The patients were grouped into three cohorts: group A included patients with normal preoperative CEA, group B included patients with elevated preoperative CEA but normal postoperative CEA, and group C included patients with elevated preoperative and postoperative CEA. Five-year overall survival (OS) was estimated by Kaplan-Meier analysis (log-rank test). Multivariate analyses were performed with Cox proportional hazard regression. Results: A total of 1662 patients with stage I-III lung cancer were enrolled in our study. Patients with normal preoperative CEA had 15.9 and 20.1% better 3- and 5-year OS rates than the cohort with elevated preoperative CEA (p < 0.001). Furthermore, group C had 36.0 and 26.6% lower 5-year OS rates (n = 74, 32.4%) than group A (n = 1188, 68.4%) and group B (n = 139, 59.0%) (p < 0.001). Group B had poorer OS than group A (p = 0.016). For patients with different pathological TNM stages, subgroup analyses showed that group C had the shortest OS in stages I and II (p < 0.05), and patients with a post-preoperative CEA increment had poorer OS than those without an increment (p = 0.029). Multivariate analyses suggested that group C (HR = 2.0, 95% CI, 1.5–2.7, p < 0.001) rather than the group with normalized postoperative CEA (HR = 1.2, 95% CI, 0.9–1.5, p = 0.270) was an independent prognostic factor. In subgroup analysis of adenocarcinoma (ADC), survival analyses suggested that group C predicted a worse prognosis. Multivariate analysis of ADC indicated that group C was an independent adverse prognostic factor (HR = 1.9, 95% CI, 1.4–2.7, p < 0.001). Conclusions: Combined elevated preoperative and postoperative CEA is an independent adverse prognostic factor for stage I-III lung adenocarcinoma. Additionally, routine perioperative detection of serum CEA can yield valuable prognostic information for patients after lung cancer surgery. |
format | Online Article Text |
id | pubmed-8578711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85787112021-11-11 Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome Jiao, Zonglin Cao, Shoubo Li, Jianhua Hu, Nan Gong, Yinghui Wang, Linduo Jin, Shi Front Mol Biosci Molecular Biosciences Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods: This retrospective cohort analysis included consecutive patients with stage I-III lung cancer who underwent curative resection between December 2010 and December 2014. The patients were grouped into three cohorts: group A included patients with normal preoperative CEA, group B included patients with elevated preoperative CEA but normal postoperative CEA, and group C included patients with elevated preoperative and postoperative CEA. Five-year overall survival (OS) was estimated by Kaplan-Meier analysis (log-rank test). Multivariate analyses were performed with Cox proportional hazard regression. Results: A total of 1662 patients with stage I-III lung cancer were enrolled in our study. Patients with normal preoperative CEA had 15.9 and 20.1% better 3- and 5-year OS rates than the cohort with elevated preoperative CEA (p < 0.001). Furthermore, group C had 36.0 and 26.6% lower 5-year OS rates (n = 74, 32.4%) than group A (n = 1188, 68.4%) and group B (n = 139, 59.0%) (p < 0.001). Group B had poorer OS than group A (p = 0.016). For patients with different pathological TNM stages, subgroup analyses showed that group C had the shortest OS in stages I and II (p < 0.05), and patients with a post-preoperative CEA increment had poorer OS than those without an increment (p = 0.029). Multivariate analyses suggested that group C (HR = 2.0, 95% CI, 1.5–2.7, p < 0.001) rather than the group with normalized postoperative CEA (HR = 1.2, 95% CI, 0.9–1.5, p = 0.270) was an independent prognostic factor. In subgroup analysis of adenocarcinoma (ADC), survival analyses suggested that group C predicted a worse prognosis. Multivariate analysis of ADC indicated that group C was an independent adverse prognostic factor (HR = 1.9, 95% CI, 1.4–2.7, p < 0.001). Conclusions: Combined elevated preoperative and postoperative CEA is an independent adverse prognostic factor for stage I-III lung adenocarcinoma. Additionally, routine perioperative detection of serum CEA can yield valuable prognostic information for patients after lung cancer surgery. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8578711/ /pubmed/34778369 http://dx.doi.org/10.3389/fmolb.2021.686313 Text en Copyright © 2021 Jiao, Cao, Li, Hu, Gong, Wang and Jin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Jiao, Zonglin Cao, Shoubo Li, Jianhua Hu, Nan Gong, Yinghui Wang, Linduo Jin, Shi Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title | Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title_full | Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title_fullStr | Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title_full_unstemmed | Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title_short | Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome |
title_sort | clinical associations of preoperative and postoperative serum cea and lung cancer outcome |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578711/ https://www.ncbi.nlm.nih.gov/pubmed/34778369 http://dx.doi.org/10.3389/fmolb.2021.686313 |
work_keys_str_mv | AT jiaozonglin clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT caoshoubo clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT lijianhua clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT hunan clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT gongyinghui clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT wanglinduo clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome AT jinshi clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome |